Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review: Epidemiology

B Jayathilaka; F Mian; F Franchini; G Au-Yeung; M IJzerman

Journal article

Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review: Epidemiology

B Jayathilaka, F Mian, F Franchini, G Au-Yeung, M IJzerman

British Journal of Cancer | Published : 2025

DOI: 10.1038/s41416-024-02887-1

Download PDF

Abstract

Background: Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence. This paper presents a systematic review that reports the prevalence of irAE by cancer type and ICI. Methods: A systematic review was undertaken in MEDLINE OVID, EMBASE and Web of Science databases from 2017–2021. A total of 293 studies were identified for analysis and, of these, event rate was calculated for 272 studies, which involved 58,291 patients with irAE among 305,879 total patients on ICI. Event rate was calculated by irAE and ICI type. Results: Mean event rate for general irAE occurrence acro..

View full abstract

University of Melbourne Researchers

Fanny Franchini Author

George Au-Yeung Author

Maarten IJzerman Author

Related Projects (3)

Collaboration Agreement for Value Based Healthcare Project 5.2 Immuno-oncology related adverse events: feasiblity of risk prediction in clinical practice.

Value Based Healthcare Program

PRedicting the population health economic IMpact of current and new CAncer Treatments (PRIMCAT)

Dr Fanny Franchini and Professor Maarten IJzerman, together with colleagues in the University of Melbourne, the University of New South Wale..

Grants

Awarded by Victorian Comprehensive Cancer Centre Alliance

Funding Acknowledgements

The authors thank Faiza Hoda, Mandy Lin and Teresa Nguyen for assisting with screening of studies and also Jo Cockwill and Stephen Glenfield for providing consumer perspectives for this research. This study is part of graduate research supported by an Australian Government Research Training Program (RTP) Scholarship and was supported by resources from the Victorian Comprehensive Cancer Centre Alliance as part of the Strategic Program Plan 2021-2024.